Daily Stock Analysis, IMMY, Imprimis Pharmaceuticals Inc, priceseries

Imprimis Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
5.25
Close
5.69
High
5.82
Low
5.25
Previous Close
6.16
Daily Price Gain
-0.47
YTD High
6.75
YTD High Date
Jan 10, 2019
YTD Low
4.93
YTD Low Date
Jan 4, 2019
YTD Price Change
0.29
YTD Gain
5.37%
52 Week High
6.75
52 Week High Date
Jan 10, 2019
52 Week Low
1.67
52 Week Low Date
Feb 22, 2018
52 Week Price Change
3.98
52 Week Gain
232.75%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 21. 2016
2.01
Jan 24. 2017
2.63
21 Trading Days
30.85%
Link
LONG
Feb 13. 2017
2.35
Feb 22. 2017
2.50
6 Trading Days
6.39%
Link
LONG
Mar 22. 2017
2.48
Apr 6. 2017
3.51
11 Trading Days
41.44%
Link
LONG
Apr 4. 2018
1.88
May 7. 2018
2.25
23 Trading Days
19.77%
Link
LONG
Aug 6. 2018
2.46
Aug 27. 2018
2.96
15 Trading Days
20.24%
Link
LONG
Oct 12. 2018
2.95
Nov 13. 2018
4.12
22 Trading Days
39.73%
Link
LONG
Dec 7. 2018
4.94
Dec 17. 2018
5.27
6 Trading Days
6.76%
Link
LONG
Jan 4. 2019
5.39
Jan 16. 2019
5.66
8 Trading Days
5.06%
Link
Company Information
Stock Symbol
IMMY
Exchange
NasdaqCM
Company URL
http://www.imprimispharma.com
Company Phone
858-704-4042
CEO
Mark L. Baum
Headquarters
California
Business Address
12264 EL CAMINO REAL, SUITE 350, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001360214
About

Imprimis Pharmaceuticals, Inc. engages in the development, production, and dispensing of innovative proprietary compounded pharmaceuticals. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in San Diego, CA.

Description

Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The company's medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.